A French contraceptive firm, HRS Pharma, has claimed that its morning-after pill doesn't work for women weighing 80kg and above.
The company made the revelation after findings of a study of levonorgestrel, a key ingredient in its Norlevo emergency contraceptive, were published, the Guardian reported.
However, Anna Glasier, a lead author of the study, said that the research wasn't particularly aimed at studying the effect of weight on emergency contraception and merely included about 1,700 women.
But, the French contraceptive maker has decided to issue a warning related to the drug's inefficiency in overweight women along with the packaging.
A spokeswoman for UK's Faculty of Sexual and Reproductive Healthcare said that in overweight and obese ladies the drug probably gets absorbed into their fat more quickly and doesn't have enough time to delay ovulation.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app